» Articles » PMID: 11784876

Paternally Inherited Inactivating Mutations of the GNAS1 Gene in Progressive Osseous Heteroplasia

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2002 Jan 11
PMID 11784876
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Progressive osseous heteroplasia (POH), an autosomal dominant disorder, is characterized by extensive dermal ossification during childhood, followed by disabling and widespread heterotopic ossification of skeletal muscle and deep connective tissue. Occasional reports of mild heterotopic ossification in Albright's hereditary osteodystrophy (AHO) and a recent report of two patients with AHO who had atypically extensive heterotopic ossification suggested a common genetic basis for the two disorders. AHO is caused by heterozygous inactivating mutations in the GNAS1 gene that result in decreased expression or function of the alpha subunit of the stimulatory G protein (Gsalpha) of adenylyl cyclase.

Methods: We tested the hypothesis that GNAS1 mutations cause POH, using the polymerase chain reaction to amplify GNAS1 exons and exon-intron boundaries in 18 patients with sporadic or familial POH.

Results: Heterozygous inactivating GNAS1 mutations were identified in 13 of the 18 probands with POH. The defective allele in POH is inherited exclusively from fathers, a result consistent with a model of imprinting for GNAS1. Direct evidence that the same mutation can cause either POH or AHO was observed within a single family, in which the phenotype correlated with the parental origin of the mutant allele.

Conclusions: Paternally inherited inactivating GNAS1 mutations cause POH. This finding extends the range of phenotypes derived from haplo insufficiency of GNAS1, provides evidence that imprinting is a regulatory mechanism for GNAS1 expression, and suggests that Gsalpha is a critical negative regulator of osteogenic commitment in nonosseous connective tissues.

Citing Articles

Late-Onset Progressive Osseous Heteroplasia: 2 Unrelated Cases and Use of Positron Emission Tomography for Diagnosis.

Pham M, Mahan J, Shah S, Estes S, Kaler S JCEM Case Rep. 2025; 3(3):luae204.

PMID: 40008392 PMC: 11850303. DOI: 10.1210/jcemcr/luae204.


Heterotopic ossification: Current developments and emerging potential therapies.

Bei M, Cao Q, Zhao C, Xiao Y, Chen Y, Xiao H Chin Med J (Engl). 2025; 138(4):389-404.

PMID: 39819765 PMC: 11845195. DOI: 10.1097/CM9.0000000000003244.


Progressive osseous heteroplasia in a five-month-old boy with a mutation in exon 9 of : a case report.

Jiang L, Li Z Am J Transl Res. 2024; 16(11):6835-6840.

PMID: 39678607 PMC: 11645640. DOI: 10.62347/WVMV7029.


"Heterotopic ossification after total hip arthroplasty through direct anterior approach without a dedicated orthopaedic table or direct lateral approach: a quasi-randomized single-center study".

Iorio R, Cantagalli M, Viglietta E, Corsetti F, Gugliotta Y, Previ L Arch Orthop Trauma Surg. 2024; 144(9):4225-4232.

PMID: 39311937 PMC: 11564372. DOI: 10.1007/s00402-024-05510-3.


Spatiotemporal Analysis of Mesenchymal Stem Cells Fate Determination by Inflammatory Niche Following Soft Tissue Injury at a Single-Cell Level.

Kan C, Tan Z, Wang H, Wang W, Yang J, Zhang Y Adv Sci (Weinh). 2024; 11(43):e2310282.

PMID: 39308190 PMC: 11578311. DOI: 10.1002/advs.202310282.